Genmab — Oktober 2015
-
-
GILD i medvind pga FDAs warning på AbbVies HepC http://news.investors.com/102215-776928-fda-warns-viekira-can-cause-liver-damange.htm?ven=yahoocp&src=aurlled&ven=yahoo
-
Tak for gode links jkj.
-
Har lagt dem i debatten.
-
Spectrum Pharmaceuticals har nemlig modtaget et såkaldt Complete Reponse Letter for lægemidlet, der er til behandling af multipel myelomatose, knoglemarvskræft. I øvrigt den samme sygdom, som Genmab og partneren Janssen forsøger at få godkendt det helt store håb, lægemiddelkandidaten daratumumab.
-
Hvad var begrundelsen?
-
-
Tak Sukker.
-
husk at EMVOMELA reelt blot er en forbedret kopi af Melhpalan
-
Det er ikke noget nyt banebrydende stof. Så mon ikke FDA bare har tænkt at de ikke kan se nok forskel til Melphalan
-
-
106 dage siden full submission. Skal vi nå det inden amerikansk vintertid?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind